FAQ/Help |
Calendar |
Search |
Today's Posts |
|
08-24-2018, 06:21 PM | #1 | ||
|
|||
Member
|
Phase 2 Trial Shows Nilotinib Potential to Modulate Dopamine in Parkinson’s
Phase 2 Trial Shows Nilotinib Potential to Modulate Dopamine in Parkinson’s |
||
Reply With Quote |
08-25-2018, 02:57 AM | #2 | ||
|
|||
Senior Member
|
I can only find the Abstract describing this research:
https://www.iaprd-world-congress.com..._Abstracts.pdf The conclusions: "a single time oral administration of Nilotinib may increase brain dopamine levels and metabolism. These results suggest Nilotinib, in a dose dependent manner, may have a symptomatic effect through modulation of brain dopamine levels. Additionally, the significant reduction of oligomeric alpha-synuclein, which is expected to increase in the CSF of PD patients as the disease progresses, suggests that Nilotinib may reduce misfolded alpha-synuclein accumulation and have a longterm disease modifying effect. Importantly, the dose response of oligomeric alpha-synuclein and HVA changes to nilotinib suggests that the dose administered may depend on the stage of disease to potentially halt PD progression." John
__________________
Born 1955. Diagnosed PD 2005. Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg |
||
Reply With Quote |
"Thanks for this!" says: | RooJr (08-25-2018) |
08-25-2018, 04:06 AM | #3 | ||
|
|||
Junior Member
|
Quote:
|
||
Reply With Quote |
08-25-2018, 06:49 AM | #4 | ||
|
|||
Member
|
I think an "abstract" is all we are likely to get for quite a while yet. As it says in the PNT article, the Georgetown Phase 2 trial is still ongoing.
|
||
Reply With Quote |
08-25-2018, 08:49 PM | #5 | ||
|
|||
Member
|
Quote:
https://www.fda.gov/forpatients/appr...st/default.htm |
||
Reply With Quote |
08-26-2018, 02:15 AM | #6 | ||
|
|||
Member
|
From the conclusion:
"Importantly, the dose response of oligomeric alpha-synuclein and HVA changes to nilotinib suggests that the dose administered may depend on the stage of disease to potentially halt PD progression." I had a lot of trouble understanding this sentence, and I found the PNT article to be of no help in that regard. Assuming I've understood it correctly, here is an alternative wording that might (or might not!) be clearer: "The dose-dependent decrease in oligomeric alpha-synuclein levels (and increase in HVA/DOPAC levels) suggests that (to potentially halt PD progression) the stage-of-disease may dictate the appropriate dose of nilotinib to administer." Anyway, it seems to me that there is still a lot of research to be done to establish the correct dose for each stage of the disease. This might well affect the prospects for a fast-track approval. Hopefully, another write-up will appear (from AlzForum, SoPD blog, ...) and shed some more light. |
||
Reply With Quote |
09-16-2018, 07:46 PM | #7 | ||
|
|||
Member
|
Quote:
|
||
Reply With Quote |
09-16-2018, 07:15 PM | #8 | ||
|
|||
Member
|
Quote:
Yes, as Jeff replied, this was only presented as an Abstract at the Oral Poster Presentation of the 2018 iaprd. This is a common occurrence to present abstracts and posters of ongoing clinical resesrch to provide updates as data is analysed. |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Gocovri Improves Dyskinesia in Parkinson’s Patients Over Long Term, Phase 3 Trial | Parkinson's Disease | |||
MRI-Focused Ultrasound Undergoing Phase 3 Clinical Trial for Parkinson’s Treatment | Parkinson's Disease | |||
Phase 2 Trial Testing Leukemia Treatment, Nilotinib | Parkinson's Disease | |||
Voyager’s Gene Therapy to Enter Phase 2/3 Trial Program for Adv Parkinson’s Dise | Parkinson's Disease | |||
Recruitment has begun for the Georgetown University "PD Nilotinib" phase 2 trial | Parkinson's Disease |